WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 … [Read more…]

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2022 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives. The … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–Kinaxis® (TSX:KXS), the authority in driving agility for fast, confident decision-making in an unpredictable world, today announced that it has scheduled its conference call to discuss the financial results for its first quarter ended March 31, 2023. The call will be hosted on Thursday, May 4 at 8:30 a.m. Eastern Time by John … [Read more…]

LONDON & BOSTON–(BUSINESS WIRE)–GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO). Herron brings a wealth of experience to Calyx, having spent more than thirty years building and growing life sciences businesses that provide advanced technology-enabled clinical scientific services to the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Deep Venous Disease Treatment Devices Market – A Global and Regional Analysis: Focus on Product, End User and Country Analysis – Analysis and Forecast, 2023-2032” report has been added to ResearchAndMarkets.com’s offering. The global deep venous disease treatment devices market was valued at $1,119.3 million in 2022 and is anticipated to reach $2,419.2 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Hepatic Encephalopathy Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031” report has been added to ResearchAndMarkets.com’s offering. The global hepatic encephalopathy therapeutics market is projected to expand at a CAGR Of 6.5% between 2023 and 2031. Companies Mentioned Mallinckrodt Pharmaceuticals Salix … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Neuromodulation Devices Global Market- Forecast To 2029” report has been added to ResearchAndMarkets.com’s offering. The neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029. The factors such as increasing prevalence of chronic pain conditions, central nervous system disorders such … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “30 Country In Vitro Diagnostic (IVD) Market Atlas” report has been added to ResearchAndMarkets.com’s offering. In Vitro Diagnostics (IVD) is a global market. To keep up, the analyst offers geographic research and analysis focused at the country, rather than the regional level in our 30 Country In Vitro Diagnostics (IVD) Market Atlas. This … [Read more…]

KYIV, Ukraine–(BUSINESS WIRE)–Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused on the development of endogenous regenerative medicines. Enamine provides Endogena with its integrated capability in … [Read more…]

AACHEN, Germany–(BUSINESS WIRE)–NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Grünenthal GmbH (the “Company”) today announced the pricing of €300 million aggregate principal amount of 6.75% … [Read more…]